Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.

Mattia BoeriMassimo MilioneClaudia ProtoDiego SignorelliGiuseppe Lo RussoCarlotta GaleoneCarla VerriMavis MensahGiovanni CentonzeAntonia MartinettiElisa SottotettiUgo PastorinoMarina Chiara GarassinoGabriella Sozzi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

The plasma MSC test could supplement PD-L1 tumor expression to identify a subgroup of patients with advanced lung cancer with worse ORR, PFS, and OS in immunotherapy regimens.

Keyphrases

poor prognosis
small cell lung cancer
binding protein
long non coding rna
clinical trial
advanced non small cell lung cancer
free survival